Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00196924
First received: September 13, 2005
Last updated: September 20, 2016
Last verified: September 2016
  Purpose
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get cervical cancer. This study will evaluate the safety and immunogenicity of GSK Biologicals HPV-16/18 vaccine over 12 months, in pre-teen and adolescent women of 10-14 years of age at study start. Approximately 2000 study subjects will receive the HPV vaccine or a control vaccine (hepatitis A vaccine) administered intramuscularly according to a 0-1-6 month schedule.

Condition Intervention Phase
Infections, Papillomavirus
Biological: HPV-16/18 L1/AS04
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Month Schedule in Healthy Female Subjects (10 - 14 Years)

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Demonstration of safety of the HPV vaccine compared to the control (occurrence of SAEs) up to month 7. [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety of HPV vaccine in entire study period. Vaccine immunogenicity. [ Designated as safety issue: No ]

Enrollment: 2067
Study Start Date: June 2004
Study Completion Date: March 2006
Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   10 Years to 14 Years   (Child)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

A woman between, and including, 10 and 14 years of age at the time of the first vaccination.

Written informed consent from the subject prior to enrolment. Subject must be free of obvious health problems. Subject must have negative urine pregnancy test.

Exclusion Criteria:

Pregnant or breastfeeding. Known acute or chronic, clinically significant pulmonary, cardiovascular, neurologic, hepatic or renal functional abnormality.

History of chronic condition(s) requiring treatment such as cancer, chronic hepatitis or kidney disease(s), diabetes, or autoimmune disease.

Previous vaccination against human papillomavirus (HPV).

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00196924

  Hide Study Locations
Locations
Australia, South Australia
GSK Investigational Site
North Adelaide, South Australia, Australia, 5006
Australia, Western Australia
GSK Investigational Site
Perth, Western Australia, Australia
Colombia
GSK Investigational Site
Bogota, Colombia, 805
GSK Investigational Site
Bogota, Colombia
Czech Republic
GSK Investigational Site
Hradec kralove, Czech Republic, 500 02
GSK Investigational Site
Pardubice, Czech Republic, 532 03
France
GSK Investigational Site
Aubevoye, France, 27940
GSK Investigational Site
Broglie, France, 27270
GSK Investigational Site
Evreux, France, 27000
GSK Investigational Site
Luynes, France, 37230
GSK Investigational Site
Nantes, France, 44300
GSK Investigational Site
Nogent le Roi, France, 28210
GSK Investigational Site
Paris, France, 75014
GSK Investigational Site
Pont De L Arche, France
GSK Investigational Site
Saint Sebastien de Morsent, France, 27180
GSK Investigational Site
Tours, France, 37000
GSK Investigational Site
Verneuil sur Avre, France, 27130
Germany
GSK Investigational Site
Deggingen, Baden-Wuerttemberg, Germany, 73326
GSK Investigational Site
Ettenheim, Baden-Wuerttemberg, Germany, 77955
GSK Investigational Site
Kehl, Baden-Wuerttemberg, Germany, 77694
GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany, 68167
GSK Investigational Site
Tauberbischofsheim, Baden-Wuerttemberg, Germany, 97941
GSK Investigational Site
Weilheim, Bayern, Germany, 82362
GSK Investigational Site
Wuerzburg, Bayern, Germany, 97070
GSK Investigational Site
Buetzow, Mecklenburg-Vorpommern, Germany, 18246
GSK Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany, 18109
GSK Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany, 18147
GSK Investigational Site
Wolfenbuettel, Niedersachsen, Germany, 38302
GSK Investigational Site
Bochum, Nordrhein-Westfalen, Germany, 44866
GSK Investigational Site
Krefeld, Nordrhein-Westfalen, Germany, 47798
GSK Investigational Site
Willich, Nordrhein-Westfalen, Germany, 47877
GSK Investigational Site
Trier, Rheinland-Pfalz, Germany, 54290
GSK Investigational Site
Bredstedt, Schleswig-Holstein, Germany, 25821
GSK Investigational Site
Brunsbuettel, Schleswig-Holstein, Germany, 25541
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany, 24937
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany, 24939
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany, 24943
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany, 24944
GSK Investigational Site
Harrislee, Schleswig-Holstein, Germany, 24955
GSK Investigational Site
Husum, Schleswig-Holstein, Germany, 25813
GSK Investigational Site
Niebuell, Schleswig-Holstein, Germany, 25899
GSK Investigational Site
Weimar, Thueringen, Germany, 99425
GSK Investigational Site
Berlin, Germany, 10315
GSK Investigational Site
Berlin, Germany, 10967
GSK Investigational Site
Hamburg, Germany, 22307
Honduras
GSK Investigational Site
Comayaguela, Honduras
Korea, Republic of
GSK Investigational Site
Seoul, Korea, Republic of, 133--792
Norway
GSK Investigational Site
Bergen, Norway, 5053
GSK Investigational Site
Oslo, Norway, 0370
Panama
GSK Investigational Site
Ciudad de Panama - La Chorrera, Panama
Spain
GSK Investigational Site
Alcora/Castellón, Spain, 12110
GSK Investigational Site
Alquerías del Niño Perdido (Castellón), Spain, 12539
GSK Investigational Site
Barcelona, Spain, 08037
GSK Investigational Site
Castellon, Spain
GSK Investigational Site
Madrid, Spain, 28046
GSK Investigational Site
Valencia, Spain, 46017
Sweden
GSK Investigational Site
Eskilstuna, Sweden, SE-631 88
GSK Investigational Site
Linköping, Sweden, SE-581 85
GSK Investigational Site
Örebro, Sweden, SE-701 85
Taiwan
GSK Investigational Site
Taipei, Taiwan, 100
GSK Investigational Site
Tao Yuan County, Taiwan, 333
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Additional Information:
Study Data/Documents: Statistical Analysis Plan  This link exits the ClinicalTrials.gov site
Identifier: 580299/013
For additional information about this study please refer to the GSK Clinical Study Register
Dataset Specification  This link exits the ClinicalTrials.gov site
Identifier: 580299/013
For additional information about this study please refer to the GSK Clinical Study Register
Informed Consent Form  This link exits the ClinicalTrials.gov site
Identifier: 580299/013
For additional information about this study please refer to the GSK Clinical Study Register
Individual Participant Data Set  This link exits the ClinicalTrials.gov site
Identifier: 580299/013
For additional information about this study please refer to the GSK Clinical Study Register. The results of this study 580299/013 are summarised with studies 104896 (M18), 104902 (M24), 104904 (M36) and 104918 (M48) on the GSK Clinical Study Register.
Study Protocol  This link exits the ClinicalTrials.gov site
Identifier: 580299/013
For additional information about this study please refer to the GSK Clinical Study Register
Clinical Study Report  This link exits the ClinicalTrials.gov site
Identifier: 580299/013
For additional information about this study please refer to the GSK Clinical Study Register
Annotated Case Report Form  This link exits the ClinicalTrials.gov site
Identifier: 580299/013
For additional information about this study please refer to the GSK Clinical Study Register

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00196924     History of Changes
Other Study ID Numbers: 580299/013 
Study First Received: September 13, 2005
Last Updated: September 20, 2016
Health Authority: Panama: Ministry of Health
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

ClinicalTrials.gov processed this record on December 02, 2016